期刊
JOURNAL OF MOLECULAR GRAPHICS & MODELLING
卷 29, 期 6, 页码 795-799出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jmgm.2011.01.002
关键词
Inverse docking; In silico screening; Protein-ligand interactions; Molecular docking
类别
资金
- OpenEye Scientific Software Inc.
- NIH [R21GM088517, R56CA86916]
- NSF [DBI-0953839]
- College of Veterinary Medicine
- University of Missouri Research Board [RB-07-32]
- Research Council Grant [URC 09-004]
- NLM Biomedical Informatics Research Training Program [115 LM07089]
- Dell
- SGI
- Sun Microsystems
- TimeLogic
- Intel
- Div Of Biological Infrastructure
- Direct For Biological Sciences [0953839] Funding Source: National Science Foundation
Inverse docking is a relatively new technique that has been used to identify potential receptor targets of small molecules. Our docking software package MDock is well suited for such an application as it is both computationally efficient, yet simultaneously shows adequate results in binding affinity predictions and enrichment tests. As a validation study, we present the first stage results of an inverse-docking study which seeks to identify potential direct targets of PRIMA-1. PRIMA-1 is well known for its ability to restore mutant p53's tumor suppressor function, leading to apoptosis in several types of cancer cells. For this reason, we believe that potential direct targets of PRIMA-1 identified in silico should be experimentally screened for their ability to inhibit cancer cell growth. The highest-ranked human protein of our PRIMA-1 docking results is oxidosqualene cyclase (OSC), which is part of the cholesterol synthetic pathway. The results of two followup experiments which treat OSC as a possible anti-cancer target are promising. We show that both PRIMA-1 and Ro 48-8071, a known potent OSC inhibitor, significantly reduce the viability of BT-474 and T47-D breast cancer cells relative to normal mammary cells. In addition, like PRIMA-1, we find that Ro 48-8071 results in increased binding of p53 to DNA in BT-474 cells (which express mutant p53). For the first time, Ro 48-8071 is shown as a potent agent in killing human breast cancer cells. The potential of OSC as a new target for developing anticancer therapies is worth further investigation. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据